Condition: Thrombosis · Injury Leg · Sponsor: Queen Mary University of London
The goal of this clinical trial is to find out the clinical and cost effectiveness of Thromboprophylaxis in participants who have been placed in a plaster cast or splint after injury. The main questions it aims to answer are: * whether giving tablets to people at high risks of clots after a leg injury is as good as injections (standard care) * whether giving any medication after a leg injury is better than standard care (advice only) for people at low risk of clots. Participants will be assessed to be high risk (TiLLI High) or low risk (TiLLI Low). People who are at high risk of clots will have either tablets or injections to reduce their risk. People at low risk will receive tablets, injections or no medication. Drug treatments will be provided for the duration of immobilisation or up to 42 days (whichever is earlier), in accordance with current NICE guidelines. The participants will be followed up for 90 days following randomisation.
This description comes directly from the study's public registry record.
Trial Manager · +44 (0) 20 7882 5555 · tilli-bjh@qmul.ac.uk
Always discuss trial participation with your own doctor first.
| Epsom and St Helier University Hospitals NHS Trust | Carshalton, Surrey, United Kingdom | Recruiting |
| Hull Teaching Hospitals NHS Trust | Hull, United Kingdom | Recruiting |
| Barts Health NHS Trust | London, United Kingdom | Recruiting |
| Kings College Hospital NHS Foundation Trust | London, United Kingdom | Recruiting |
| Northern Care Alliance NHS Foundation Trust | Manchester, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06370273